share_log

TD Cowen Maintains Buy on Calumet, Lowers Price Target to $26

Benzinga ·  Nov 11 23:58  · Ratings

TD Cowen analyst Jason Gabelman maintains Calumet (NASDAQ:CLMT) with a Buy and lowers the price target from $27 to $26.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment